

# BCBSMT HEDIS® 2014 COMPARISON REPORT - PPO

## EFFECTIVENESS OF CARE MEASURES

### BCBSMT 2012

### BCBSMT 2013

### BCBSMT 2014

### 2013 QC National

### 2014 QC National

|  | Num  | Denom  |                 | Num  | Denom  | % change        | Num    | Denom  | % change        |        |         |        |        |
|--|------|--------|-----------------|------|--------|-----------------|--------|--------|-----------------|--------|---------|--------|--------|
| <b>Childhood Immunization****</b>                                |      |        | <b>n=849</b>    |      |        | <b>n=473</b>    |        |        | <b>n=453</b>    |        |         |        |        |
| DTaP   | 442  | 849    | 52.06%          | 399  | 473    | 84.36%          | na     | 379    | 453             | 83.66% | -0.82%  | 80.00% | 80.30% |
| Hib  | 591  | 849    | 69.61%          | 426  | 473    | 90.06%          | na     | 411    | 453             | 90.73% | 0.74%   | 88.30% | 88.10% |
| IPV  | 522  | 849    | 61.48%          | 426  | 473    | 90.06%          | na     | 414    | 453             | 91.39% | 1.47%   | 86.30% | 86.20% |
| PCV  | 470  | 849    | 55.36%          | 390  | 473    | 82.45%          | na     | 391    | 453             | 86.31% | 4.68%   | 78.90% | 78.30% |
| HepB   | 400  | 849    | 47.11%          | 411  | 473    | 86.89%          | na     | 403    | 453             | 88.96% | 2.38%   | 77.30% | 76.80% |
| MMR  | 685  | 849    | 80.68%          | 421  | 473    | 89.01%          | na     | 410    | 453             | 90.51% | 1.69%   | 88.30% | 88.70% |
| VZV  | 656  | 849    | 77.27%          | 398  | 473    | 84.14%          | na     | 394    | 453             | 86.98% | 3.37%   | 88.00% | 88.30% |
| HepA ^   | 213  | 849    | 25.09%          | 339  | 473    | 71.67%          | na     | 330    | 453             | 72.85% | 1.64%   | 61.10% | 79.30% |
| Rotavirus  | 396  | 849    | 46.64%          | 331  | 473    | 69.98%          | na     | 330    | 453             | 72.85% | 4.10%   | 69.80% | 71.90% |
| Influenza  | 306  | 849    | 36.04%          | 268  | 473    | 56.66%          | na     | 243    | 453             | 53.64% | -5.33%  | 59.80% | 61.10% |
| Combo-1  | na   | 849    | na              | 398  | 473    | 84.14%          | na     | 358    | 453             | 79.03% | -6.08%  | na     | na     |
| Combo-2  | 304  | 849    | 35.81%          | 358  | 473    | 75.69%          | na     | 343    | 453             | 75.72% | 0.04%   | 68.10% | 67.50% |
| Combo-3  | 293  | 849    | 34.51%          | 339  | 473    | 71.67%          | na     | 337    | 453             | 74.39% | 3.80%   | 65.80% | 66.40% |
| Combo-4 ^  | 95   | 849    | 11.19%          | 282  | 473    | 59.62%          | na     | 279    | 453             | 61.59% | 3.30%   | na     | na     |
| Combo-5  | 222  | 849    | 26.15%          | 273  | 473    | 57.72%          | na     | 276    | 453             | 60.93% | 5.56%   | na     | na     |
| Combo-6  | 144  | 849    | 16.96%          | 229  | 473    | 48.41%          | na     | 209    | 453             | 46.14% | -4.70%  | na     | na     |
| Combo-7 ^  | 82   | 849    | 9.66%           | 252  | 473    | 53.28%          | na     | 247    | 453             | 54.53% | 2.34%   | na     | na     |
| Combo-8 ^  | 56   | 849    | 6.60%           | 202  | 473    | 42.71%          | na     | 181    | 453             | 39.96% | -6.44%  | na     | na     |
| Combo-9  | 123  | 849    | 14.49%          | 201  | 473    | 42.49%          | na     | 177    | 453             | 39.07% | -8.05%  | na     | na     |
| Combo-10 ^   | 53   | 849    | 6.24%           | 188  | 473    | 39.75%          | na     | 160    | 453             | 35.32% | -11.14% | 29.50% | 38.70% |
| <b>Adolescent Immunizations****</b>                              |      |        | <b>n=1111</b>   |      |        | <b>n=471</b>    |        |        | <b>n=450</b>    |        |         |        |        |
| Meningococcal (MCV)  | 373  | 1111   | 33.57%          | 202  | 471    | 42.89%          | na     | 204    | 450             | 45.33% | 5.70%   | 57.10% | 60.60% |
| Tdap/Td  | 668  | 1111   | 60.13%          | 390  | 471    | 82.80%          | na     | 353    | 450             | 78.44% | -5.26%  | 69.90% | 72.90% |
| Combo-1  | 356  | 1111   | 32.04%          | 201  | 471    | 42.68%          | na     | 201    | 450             | 44.67% | 4.67%   | 54.30% | 58.20% |
| <b>HPV Vaccine for Female Adolescents****</b>                    |      |        | <b>n=571</b>    |      |        | <b>n=472</b>    |        |        | <b>n=448</b>    |        |         |        |        |
|  | 50   | 571    | 8.76%           | 43   | 472    | 9.11%           | na     | 53     | 448             | 11.83% | 29.86%  | na     | 10.90% |
| <b>Appropriate Tx for Children w/ URI</b>                        |      |        | <b>n=1900</b>   |      |        | <b>n=1484</b>   |        |        | <b>n=1925</b>   |        |         |        |        |
|  | 1520 | 1900   | 80.00%          | 1184 | 1484   | 79.78%          | -0.27% | 1555   | 1925            | 80.78% | 1.25%   | 82.30% | 83.20% |
| <b>Appropriate Testing for Children w/ Pharyngitis</b>           |      |        | <b>n=1523</b>   |      |        | <b>n=1102</b>   |        |        | <b>n=1074</b>   |        |         |        |        |
|  | 1095 | 1523   | 71.90%          | 772  | 1102   | 70.05%          | -2.56% | 756    | 1074            | 70.39% | 0.48%   | 78.90% | 78.40% |
| <b>Avoidance of Antibiotic Tx for Adults w/ Acute Bronchitis</b> |      |        | <b>n=1356</b>   |      |        | <b>n=1289</b>   |        |        | <b>n=1410</b>   |        |         |        |        |
|  | 296  | 1356   | 21.83%          | 270  | 1289   | 20.95%          | -4.04% | 358    | 1410            | 25.39% | 21.21%  | 21.40% | 23.80% |
| <b>Colorectal Cancer Screening</b>                               |      |        | <b>n=22,436</b> |      |        | <b>n=22,096</b> |        |        | <b>n=30,155</b> |        |         |        |        |
|  | 8437 | 22,436 | 37.60%          | 9186 | 22,096 | 41.57%          | 10.55% | 12,324 | 30,155          | 40.87% | -1.69%  | 55.80% | 56.50% |

| EFFECTIVENESS OF CARE MEASURES                                  | BCBSMT 2012     |        | BCBSMT 2013     |        | % change | BCBSMT 2014     |         | % change | 2013 QC National | 2014 QC National |         |        |        |
|---|-----------------|--------|-----------------|--------|----------|-----------------|---------|----------|------------------|------------------|---------|--------|--------|
|   | Num             | Denom  | Num             | Denom  |          | Num             | Denom   |          |                  |                  |         |        |        |
| <b>Breast Cancer Screening^^</b>                                | <b>n=17,487</b> |        | <b>n=16,948</b> |        |          | <b>n=12,105</b> |         |          |                  |                  |         |        |        |
|   | 11,514          | 17,487 | 65.84%          | 11,136 | 16,948   | 65.71%          | -0.21%  | 8741     | 12,105           | 72.21%           | 9.90%   | 66.50% | 69.50% |
| <b>Cervical Cancer Screening^^^</b>                             | <b>n=21,765</b> |        | <b>n=16,820</b> |        |          | <b>n=19,974</b> |         |          |                  |                  |         |        |        |
|   | 15,535          | 21,765 | 71.38%          | 11,964 | 16,820   | 71.13%          | -0.35%  | 14,313   | 19,974           | 71.66%           | 0.74%   | 73.60% | na     |
| <b>Persistence of Beta Blocker Treatment after Heart Attack</b> | <b>n=49</b>     |        | <b>n=46</b>     |        |          | <b>n=59</b>     |         |          |                  |                  |         |        |        |
|   | 41              | 49     | 83.67%          | 38     | 46       | 82.61%          | -1.27%  | 44       | 59               | 74.58%           | -9.72%  | 79.50% | 81.40% |
| <b>Controlling High Blood Pressure</b>                          | <b>n=na</b>     |        | <b>n=na</b>     |        |          | <b>n=447</b>    |         |          |                  |                  |         |        |        |
| Blood Pressure < 140/90 mmHg                                    | na              | na     | na              | na     | na       | na              | na      | 291      | 447              | 65.10%           | na      | 57.40% | 57.60% |
| <b>Cholesterol Management for Patients****</b>                  | <b>n=587</b>    |        | <b>n=461</b>    |        |          | <b>n=453</b>    |         |          |                  |                  |         |        |        |
| w/ Cardiovascular Conditions                                    |                 |        |                 |        |          |                 |         |          |                  |                  |         |        |        |
| LDL-screening   | 436             | 587    | 74.28%          | 373    | 461      | 80.91%          | 8.93%   | 349      | 453              | 77.04%           | -4.78%  | 83.70% | 82.60% |
| <b>Comprehensive Diabetes Care****</b>                          | <b>n=2805</b>   |        | <b>n=617</b>    |        |          | <b>n=597</b>    |         |          |                  |                  |         |        |        |
| HbA1c Tested  | 2370            | 2805   | 84.49%          | 548    | 617      | 88.82%          | 5.12%   | 545      | 597              | 91.29%           | 2.78%   | 87.20% | 87.30% |
| Poor HbA1c Control >9.0% *                                      | na              | 2805   | na              | 220    | 617      | 35.66%          | na      | 140      | 597              | 23.45%           | -34.23% | 35.20% | 37.60% |
| HbA1c < 8.0%  | na              | 2805   | na              | 337    | 617      | 54.62%          | na      | 389      | 597              | 65.16%           | 19.30%  | 54.50% | 52.90% |
| HbA1c < 7.0% **   | na              | 2188   | na              | 135    | 433      | 31.18%          | na      | 212      | 470              | 45.11%           | 44.67%  | 36.00% | 32.40% |
| Eye Exam  | 1011            | 2805   | 36.04%          | 336    | 617      | 54.46%          | 51.09%  | 325      | 597              | 54.44%           | -0.03%  | 48.80% | 46.90% |
| LDL Screening   | 1921            | 2805   | 68.48%          | 465    | 617      | 75.36%          | 10.05%  | 459      | 597              | 76.88%           | 2.02%   | 81.70% | 81.30% |
| LDL Level < 130 mg/dL   | na              | 2805   | na              | 317    | 617      | 51.38%          | na      | 354      | 597              | 59.30%           | 15.41%  | na     | na     |
| LDL Level < 100 mg/dL   | na              | 2805   | na              | 222    | 617      | 35.98%          | na      | 243      | 597              | 40.70%           | 13.13%  | 41.70% | 40.80% |
| Nephropathy Monitored   | 2036            | 2805   | 72.58%          | 479    | 617      | 77.63%          | 6.96%   | 489      | 597              | 81.91%           | 5.51%   | 78.60% | 78.80% |
| Blood Pressure < 140/80 mmHg                                    | na              | 2805   | na              | 262    | 617      | 42.46%          | na      | 277      | 597              | 46.40%           | 9.27%   | 37.50% | 37.60% |
| Blood Pressure < 140/90 mmHg                                    | na              | 2805   | na              | 377    | 617      | 61.10%          | na      | 418      | 597              | 70.02%           | 14.59%  | 58.30% | 58.50% |
| <b>Follow-up for Mental Illness</b>                             | <b>n=167</b>    |        | <b>n=294</b>    |        |          | <b>n=260</b>    |         |          |                  |                  |         |        |        |
| 7 days  | 80              | 167    | 47.90%          | 146    | 294      | 49.66%          | 3.66%   | 122      | 260              | 46.92%           | -5.51%  | 53.00% | 49.80% |
| 30 days   | 127             | 167    | 76.05%          | 207    | 294      | 70.41%          | -7.42%  | 176      | 260              | 67.69%           | -3.86%  | 72.20% | 69.00% |
| <b>Antidepressant Medication Management</b>                     | <b>n=620</b>    |        | <b>n=746</b>    |        |          | <b>n=1141</b>   |         |          |                  |                  |         |        |        |
| Effective Acute Phase Tx  | 418             | 620    | 67.42%          | 532    | 746      | 71.31%          | 5.78%   | 773      | 1141             | 67.75%           | -5.00%  | 68.90% | 64.30% |
| Effective Continuation Phase TX                                 | 316             | 620    | 50.97%          | 402    | 746      | 53.89%          | 5.73%   | 593      | 1141             | 51.97%           | -3.55%  | 53.40% | 48.70% |
| <b>Follow-Up for Children Prescribed</b>                        | <b>n=136</b>    |        | <b>n=142</b>    |        |          | <b>n=160</b>    |         |          |                  |                  |         |        |        |
| <b>ADHD Medication</b>  |                 |        |                 |        |          |                 |         |          |                  |                  |         |        |        |
| Initiation Phase Visit  | 56              | 136    | 41.18%          | 47     | 142      | 33.10%          | -19.62% | 59       | 160              | 36.88%           | 11.41%  | 38.10% | 38.20% |
| Continuation Phase  | 12              | 32     | 37.50%          | 11     | 37       | 29.73%          | -20.72% | 19       | 33               | 57.58%           | 93.66%  | 44.90% | 45.20% |
| <b>Use of Appropriate Medications for People with Asthma</b>    | <b>n=812</b>    |        | <b>n=739</b>    |        |          | <b>n=810</b>    |         |          |                  |                  |         |        |        |
| Ages 5-11   | 78              | 87     | 89.66%          | 65     | 67       | 97.01%          | 8.21%   | 58       | 60               | 96.67%           | -0.36%  | 95.70% | 96.20% |

**EFFECTIVENESS OF CARE MEASURES**

|  | BCBSMT 2012 |       |               | BCBSMT 2013 |       |               | % change | BCBSMT 2014 |       |                 | % change | 2013 QC National | 2014 QC National |
|--|-------------|-------|---------------|-------------|-------|---------------|----------|-------------|-------|-----------------|----------|------------------|------------------|
|  | Num         | Denom |               | Num         | Denom |               |          | Num         | Denom |                 |          |                  |                  |
| Ages 12-18   | 75          | 82    | 91.46%        | 74          | 79    | 93.67%        | 2.41%    | 61          | 71    | 85.92%          | -8.28%   | 92.20%           | 93.10%           |
| Ages 19-50   | 316         | 364   | 86.81%        | 289         | 345   | 83.77%        | -3.51%   | 331         | 391   | 84.65%          | 1.06%    | 87.40%           | 87.10%           |
| Ages 51-64   | 256         | 279   | 91.76%        | 224         | 248   | 90.32%        | -1.56%   | 265         | 288   | 92.01%          | 1.87%    | 92.20%           | 92.00%           |
| Combined   | 725         | 812   | 89.29%        | 652         | 739   | 88.23%        | -1.19%   | 715         | 810   | 88.27%          | 0.05%    | 90.70%           | 90.50%           |
| <b>Medications Management for People with Asthma (75%)</b>         |             |       |               |             |       |               |          |             |       |                 |          |                  |                  |
|  |             |       | <i>n=725</i>  |             |       | <i>n=652</i>  |          |             |       | <i>n=715</i>    |          |                  |                  |
| Ages 5-11  | 32          | 78    | 41.03%        | 16          | 65    | 24.62%        | -40.00%  | 17          | 58    | 29.31%          | 19.07%   | 34.50%           | 42.80%           |
| Ages 12-18   | 25          | 75    | 33.33%        | 29          | 74    | 39.19%        | 17.57%   | 22          | 61    | 36.07%          | -7.97%   | 34.10%           | 38.80%           |
| Ages 19-50   | 109         | 316   | 34.49%        | 107         | 289   | 37.02%        | 7.34%    | 132         | 331   | 39.88%          | 7.71%    | 42.10%           | 47.90%           |
| Ages 51-64   | 137         | 256   | 53.52%        | 120         | 224   | 53.57%        | 0.10%    | 148         | 265   | 55.85%          | 4.25%    | 55.60%           | 59.80%           |
| Combined   | 303         | 725   | 41.79%        | 272         | 652   | 41.72%        | -0.18%   | 319         | 715   | 44.62%          | 6.95%    | 43.50%           | 49.60%           |
| <b>Asthma Medication Ratio</b>                                     |             |       |               |             |       |               |          |             |       |                 |          |                  |                  |
|  |             |       | <i>n=na</i>   |             |       | <i>n=736</i>  |          |             |       | <i>n=808</i>    |          |                  |                  |
| Ages 5-11  | na          | na    | na            | 52          | 67    | 77.61%        | na       | 49          | 59    | 83.05%          | 7.01%    | na               | 89.70%           |
| Ages 12-18   | na          | na    | na            | 66          | 79    | 83.54%        | na       | 45          | 71    | 63.38%          | -24.14%  | na               | 79.90%           |
| Ages 19-50   | na          | na    | na            | 230         | 345   | 66.67%        | na       | 270         | 390   | 69.23%          | 3.85%    | na               | 71.80%           |
| Ages 51-64   | na          | na    | na            | 196         | 248   | 79.03%        | na       | 240         | 288   | 83.33%          | 5.44%    | na               | 82.90%           |
| Combined   | na          | na    | na            | 545         | 736   | 74.05%        | na       | 604         | 808   | 74.75%          | 0.95%    | na               | 78.40%           |
| <b>Use of Spirometry in the Assessment &amp; Diagnoses of COPD</b> |             |       |               |             |       |               |          |             |       |                 |          |                  |                  |
|  |             |       | <i>n=195</i>  |             |       | <i>n=182</i>  |          |             |       | <i>n=218</i>    |          |                  |                  |
|  | 60          | 195   | 30.77%        | 68          | 182   | 37.36%        | 21.43%   | 74          | 218   | 33.94%          | -9.15%   | 41.50%           | 41.00%           |
| <b>Pharmacotherapy Management of COPD Exacerbation</b>             |             |       |               |             |       |               |          |             |       |                 |          |                  |                  |
|  |             |       | <i>n=45</i>   |             |       | <i>n=40</i>   |          |             |       | <i>n=51</i>     |          |                  |                  |
| Bronchodilator   | 30          | 45    | 66.67%        | 30          | 40    | 75.00%        | 12.50%   | 41          | 51    | 80.39%          | 7.19%    | 77.70%           | 78.70%           |
| Systemic Corticosteroid  | 26          | 45    | 57.78%        | 34          | 40    | 85.00%        | 47.12%   | 30          | 51    | 58.82%          | -30.80%  | 70.80%           | 72.80%           |
| <b>Chlamydia Screening</b>   |             |       |               |             |       |               |          |             |       |                 |          |                  |                  |
|  |             |       | <i>n=3843</i> |             |       | <i>n=5241</i> |          |             |       | <i>n=4704</i>   |          |                  |                  |
| Ages 16-20   | 525         | 1681  | 31.23%        | 792         | 2233  | 35.47%        | 13.57%   | 633         | 2004  | 31.59%          | -10.94%  | 38.90%           | 37.80%           |
| Ages 21-24   | 814         | 2162  | 37.65%        | 1157        | 3008  | 38.46%        | 2.16%    | 976         | 2700  | 36.15%          | -6.02%   | 45.50%           | 45.90%           |
| Combined   | 1339        | 3843  | 34.84%        | 1949        | 5241  | 37.19%        | 6.73%    | 1609        | 4704  | 34.20%          | -8.02%   | 42.30%           | 42.20%           |
| <b>Use of Imaging Studies for Low Back Pain</b>                    |             |       |               |             |       |               |          |             |       |                 |          |                  |                  |
|  |             |       | <i>n=1797</i> |             |       | <i>n=1814</i> |          |             |       | <i>n=2050</i>   |          |                  |                  |
|  | 1465        | 1797  | 81.52%        | 1488        | 1814  | 82.03%        | 0.62%    | 1672        | 2050  | 81.56%          | -0.57%   | 74.20%           | 74.40%           |
| <b>DMARD Therapy in Rheumatoid Arthritis</b>                       |             |       |               |             |       |               |          |             |       |                 |          |                  |                  |
|  |             |       | <i>n=311</i>  |             |       | <i>n=357</i>  |          |             |       | <i>n=417</i>    |          |                  |                  |
|  | 279         | 311   | 88.89%        | 314         | 357   | 87.96%        | -1.05%   | 361         | 417   | 86.57%          | -1.57%   | 87.20%           | 87.20%           |
| <b>Annual Monitoring for Patients on Persistent Medications</b>    |             |       |               |             |       |               |          |             |       |                 |          |                  |                  |
|  |             |       | <i>n=9539</i> |             |       | <i>n=9623</i> |          |             |       | <i>n=11,386</i> |          |                  |                  |
| ACE/ARB  | 3833        | 5254  | 72.95%        | 3782        | 5344  | 70.77%        | -2.99%   | 4604        | 6414  | 71.78%          | 1.43%    | 79.20%           | 80.40%           |
| Anticonvulsant   | 124         | 230   | 53.91%        | 108         | 200   | 54.00%        | 0.16%    | 109         | 209   | 52.15%          | -3.42%   | 56.30%           | 56.10%           |
| Digoxin  | 103         | 122   | 84.43%        | 78          | 97    | 80.41%        | -4.75%   | 80          | 99    | 80.81%          | 0.49%    | 80.60%           | 82.30%           |

**EFFECTIVENESS OF CARE MEASURES**

**BCBSMT 2012**

**BCBSMT 2013**

**BCBSMT 2014**

**2013 QC National**

**2014 QC National**

|          | Num  | Denom |               | Num  | Denom |               | % change      | Num  | Denom  |               | % change     |               |               |
|----------|------|-------|---------------|------|-------|---------------|---------------|------|--------|---------------|--------------|---------------|---------------|
| Diuretic | 2820 | 3933  | <b>71.70%</b> | 2833 | 3982  | <b>71.15%</b> | <b>-0.78%</b> | 3329 | 4664   | <b>71.38%</b> | <b>0.33%</b> | <b>78.70%</b> | <b>79.90%</b> |
| Combined | 6880 | 9539  | <b>72.12%</b> | 6801 | 9623  | <b>70.67%</b> | <b>-2.01%</b> | 8122 | 11,386 | <b>71.33%</b> | <b>0.93%</b> | <b>78.50%</b> | <b>79.80%</b> |

\* Note: For this numerator, a lower rate indicates better performance.

\*\* Note: The HbA1c < 7.0% denominator excludes members w/ certain conditions. Please see measure description for a list of conditions.

\*\*\*Note: Medical record review was completed on these measures for HEDIS 2013 & 2014, but not HEDIS 2012.

\*\*\*\*Note: Medical record review was completed on these measures for HEDIS 2013, but not HEDIS 2012 or 2014.

^Note: The NCQA qualifying dosing requirements for the Hepatis A immunizations series changed from 2 doses in 2012 to 1 dose in 2013 & 2014.

^^ Note: The Breast Cancer Screening age qualifying range for women changed to women age 50-74 years in 2014 from 40-74 years in 2013 & 2012.

^^^ Note: The Cervical Cancer Screening screening frequency in 2014 changed to allow two screening methods. For women who had cervical cytology/HPV co-testing, the screening frequency is extended to every 5 years. For women with only cervical cytology testing, the screening frequency remains every 3 years.

BCBSMT 2012 rates based on 2011 data.

BCBSMT 2013 rates based on 2012 data.

BCBSMT 2014 rates based on 2013 data.

The 2014 QC (Quality Compass®) rate comparisons are from NCQA's *State of Health Care Quality 2014 Report* and reflect 2013 data.

The 2013 QC (Quality Compass®) rate comparisons are from NCQA's *State of Health Care Quality 2013 Report* and reflect 2012 data.